MA51945A1 - Variant d'antigène du virus varicelle-zona et utilisation associée - Google Patents

Variant d'antigène du virus varicelle-zona et utilisation associée

Info

Publication number
MA51945A1
MA51945A1 MA51945A MA51945A MA51945A1 MA 51945 A1 MA51945 A1 MA 51945A1 MA 51945 A MA51945 A MA 51945A MA 51945 A MA51945 A MA 51945A MA 51945 A1 MA51945 A1 MA 51945A1
Authority
MA
Morocco
Prior art keywords
antigen variant
vaccine
varicella zoster
zoster virus
virus antigen
Prior art date
Application number
MA51945A
Other languages
English (en)
Other versions
MA51945B2 (fr
Inventor
Hyo Jung Nam
Ga Young Ji
Eunmi Kim
Original Assignee
Mogam Inst Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Inst Biomedical Res filed Critical Mogam Inst Biomedical Res
Publication of MA51945A1 publication Critical patent/MA51945A1/fr
Publication of MA51945B2 publication Critical patent/MA51945B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16771—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un variant d'antigène et son utilisation, le variant d'antigène étant une protéine, parmi des protéines de surface (ge) du virus varicelle-zona, présentant un niveau d'expression élevé et une haute immunogénicité. Le variant d'antigène fourni par la présente invention peut être utilisé en tant que composition de vaccin permettant ainsi à la composition de vaccin d'avoir une meilleure sécurité par comparaison avec un vaccin à virus vivant; le variant d'antigène présente un niveau d'expression plus élevé dans une cellule hôte par comparaison avec d'autres antigènes, et est donc utile en tant que vaccin pour la prévention ou le traitement de la varicelle ou du zona provoquées par le virus varicelle-zona.
MA51945A 2018-05-23 2019-05-22 Variant d'antigène du virus varicelle-zona et utilisation associée MA51945B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180058219 2018-05-23
PCT/KR2019/006113 WO2019225962A1 (fr) 2018-05-23 2019-05-22 Variant d'antigène du virus varicelle-zona et utilisation associée

Publications (2)

Publication Number Publication Date
MA51945A1 true MA51945A1 (fr) 2021-09-30
MA51945B2 MA51945B2 (fr) 2023-08-31

Family

ID=68616069

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51945A MA51945B2 (fr) 2018-05-23 2019-05-22 Variant d'antigène du virus varicelle-zona et utilisation associée

Country Status (19)

Country Link
US (1) US11642408B2 (fr)
EP (1) EP3812394A4 (fr)
JP (1) JP7247226B2 (fr)
KR (1) KR20210006460A (fr)
CN (1) CN112189017A (fr)
AU (1) AU2019272184B2 (fr)
BR (1) BR112020023642A2 (fr)
CA (1) CA3100462A1 (fr)
CO (1) CO2020015167A2 (fr)
EA (1) EA202092828A1 (fr)
IL (1) IL278892A (fr)
MA (1) MA51945B2 (fr)
MX (1) MX2020012469A (fr)
MY (1) MY195490A (fr)
PE (1) PE20201415A1 (fr)
PH (1) PH12020552009A1 (fr)
UA (1) UA126460C2 (fr)
WO (1) WO2019225962A1 (fr)
ZA (1) ZA202006956B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102270048B1 (ko) 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CN113683704B (zh) * 2021-07-28 2023-05-30 安徽智飞龙科马生物制药有限公司 一种水痘-带状疱疹病毒r-gE融合蛋白、重组水痘-带状疱疹疫苗及其制备方法和应用
WO2023056912A1 (fr) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Vaccins à base d'acide nucléique pour vzv
WO2023122774A1 (fr) 2021-12-23 2023-06-29 Dynavax Technologies Corporation Immunogénicité d'un vaccin contre le zona à adjuvant cpg
CN116655748A (zh) * 2023-02-28 2023-08-29 易慧生物技术(上海)有限公司 一种截短型水痘-带状疱疹病毒gE蛋白及其应用
CN117683121B (zh) * 2024-01-30 2024-04-16 北京百普赛斯生物科技股份有限公司 抗水痘-带状疱疹病毒抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920703614A (ko) * 1990-10-04 1992-12-18 티모시 제이. 렉카르트 바리셀라-조스터 바이러스 항원
US5824319A (en) * 1990-10-04 1998-10-20 Research Corporation Technologies, Inc. Varicella-zoster virus antigen
MXPA04010902A (es) * 2004-11-03 2006-05-08 Alvaro Raul Lara Rodriguez Vacuna recombinante a partir de las proteinas ge, gi y gb del virus de varicela zoster como tratamiento y prevencion de esclerosis multiple.
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
WO2006128026A2 (fr) * 2005-05-26 2006-11-30 The United States Of America As Represented By Thesecretary, Dept. Of Health And Human Services National Institutes Of Health Recepteur cellulaire du virus varicelle-zona, methodes destinees a empecher la dissemination de la varicelle-zona et methodes destinees a augmenter la stabilite et l'infectiosite du virus
EP2670443A4 (fr) * 2011-01-31 2015-10-14 Univ Pennsylvania Molécules d'acide nucléique codant de nouveaux antigènes d'herpès, vaccin les comprenant et procédés pour les utiliser
RU2580003C2 (ru) * 2011-02-24 2016-04-10 Могам Байотекнолоджи Рисерч Инститьют Новые штаммы вируса ветряной оспы и противовирусная вакцина против ветряной оспы и опоясывающего лишая, в которой применяются такие штаммы
CN102517302A (zh) * 2011-12-28 2012-06-27 中国人民解放军军事医学科学院野战输血研究所 一种重组表达水痘-带状疱疹病毒截短型糖蛋白e的方法及其应用
KR101723605B1 (ko) * 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법
CN105669838B (zh) * 2014-12-04 2020-10-16 厦门大学 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体
MX2017008055A (es) * 2014-12-18 2017-09-28 Glaxosmithkline Biologicals Sa Vacunacion.
EP3262075B1 (fr) * 2015-02-25 2024-03-13 Mogam Institute For Biomedical Research Nouvel anticorps se liant à la tfpi et composition le comprenant
JP6367783B2 (ja) * 2015-11-26 2018-08-01 田中貴金属工業株式会社 水痘帯状疱疹ウイルス検出用免疫クロマト分析装置

Also Published As

Publication number Publication date
ZA202006956B (en) 2022-03-30
WO2019225962A1 (fr) 2019-11-28
MX2020012469A (es) 2021-02-09
PE20201415A1 (es) 2020-12-07
JP2021525079A (ja) 2021-09-24
EA202092828A1 (ru) 2021-03-11
AU2019272184A1 (en) 2021-01-14
AU2019272184B2 (en) 2022-01-27
CO2020015167A2 (es) 2020-12-21
CN112189017A (zh) 2021-01-05
PH12020552009A1 (en) 2021-06-14
MA51945B2 (fr) 2023-08-31
EP3812394A1 (fr) 2021-04-28
EP3812394A4 (fr) 2022-03-23
IL278892A (en) 2021-01-31
US11642408B2 (en) 2023-05-09
CA3100462A1 (fr) 2019-11-28
KR20210006460A (ko) 2021-01-18
JP7247226B2 (ja) 2023-03-28
BR112020023642A2 (pt) 2021-02-17
MY195490A (en) 2023-01-26
US20210187099A1 (en) 2021-06-24
UA126460C2 (uk) 2022-10-05

Similar Documents

Publication Publication Date Title
MA51945A1 (fr) Variant d'antigène du virus varicelle-zona et utilisation associée
Lelic et al. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age
CY1122790T1 (el) Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις
McDermott et al. Quantifying antigen-specific CD4 T cells during a viral infection: CD4 T cell responses are larger than we think
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
WO2018085469A3 (fr) Anticorps dirigés contre l'immunoglobuline de lymphocyte t et la protéine 3 de mucine (tim-3)
RU2010127298A (ru) Вакцинная композиция против злокачественной опухоли
PE20141658A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
RU2020132040A (ru) Общие неоантигены
EA202090652A1 (ru) T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras
BR112016015512A2 (pt) proteínas quiméricas de fator viii e suas utilizações
MX2017011796A (es) Lo nuevo complejo que comprende un peptido de penetracion celular, una molecula cargo y un agonista peptidico de tlr.
BR112018006995A2 (pt) receptores anti-cd30 de antígeno quimérico
MA40137B1 (fr) Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement
Alzhanova et al. Cowpox virus inhibits the transporter associated with antigen processing to evade T cell recognition
CO2019009480A2 (es) Composición farmacéutica de bajo ph que comprende construcciones de anticuerpos que activan linfocitos t
Srivastava et al. Human asymptomatic epitopes identified from the herpes simplex virus tegument protein VP13/14 (UL47) preferentially recall polyfunctional effector memory CD44high CD62Llow CD8+ TEM cells and protect humanized HLA-A* 02: 01 transgenic mice against ocular herpesvirus infection
JP2016509470A5 (fr)
Hamilton et al. Listeria monocytogenes infection overcomes the requirement for CD40 ligand in exogenous antigen presentation to CD8+ T cells
JP2023106591A (ja) 既存の微生物免疫を利用した癌処置
WO2020252145A1 (fr) Immunothérapies à base de néo-antigènes
Kongkaew et al. Molecular dynamics simulation reveals the selective binding of human leukocyte antigen alleles associated with Behçet's disease
CL2023000426A1 (es) Neoantígenos ras y usos de los mismos
Madden et al. Koala immunology and infectious diseases: How much can the koala bear?
Boggiatto et al. Targeted extracellular signal-regulated kinase activation mediated by Leishmania amazonensis requires MP1 scaffold